New frontiers for management of hyperkalaemia: the emergence of novel agents

por Nassif, Michael E, Kosiborod, Mikhail
Publicado 2019

Comparison of Video and Telephone Visits in Outpatients With Heart Failure

por Sammour, Yasser, Spertus, John A., Shatla, Islam, Gupta, Sanjaya K., Nassif, Michael E., Magalski, Anthony, Main, Michael L., Sperry, Brett W.
Publicado 2021

Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry

por Khariton, Yevgeniy, Fonarow, Gregg C., Hellkamp, Ann, Thomas, Laine, Nassif, Michael E., Butler, Javed, Duffy, Carol I., Albert, Nancy M., Spertus, John A.
Publicado 2020

Outpatient Management of Heart Failure During the COVID-19 Pandemic After Adoption of a Telehealth Model

por Sammour, Yasser, Spertus, John A., Austin, Bethany A., Magalski, Anthony, Gupta, Sanjaya K., Shatla, Islam, Dean, Evelyn, Kennedy, Kevin F., Jones, Philip G., Nassif, Michael E., Main, Michael L., Sperry, Brett W.
Publicado 2021

Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

por Tromp, Jasper, Ponikowski, Piotr, Salsali, Afshin, Angermann, Christiane E., Biegus, Jan, Blatchford, Jon, Collins, Sean P., Ferreira, João Pedro, Grauer, Claudia, Kosiborod, Mikhail, Nassif, Michael E., Psotka, Mitchell A., Brueckmann, Martina, Teerlink, John R., Voors, Adriaan A.
Publicado 2021

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

por Biegus, Jan, Voors, Adriaan A, Collins, Sean P, Kosiborod, Mikhail N, Teerlink, John R, Angermann, Christiane E, Tromp, Jasper, Ferreira, Joao Pedro, Nassif, Michael E, Psotka, Mitchell A, Brueckmann, Martina, Salsali, Afshin, Blatchford, Jonathan P, Ponikowski, Piotr
Publicado 2022

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial

por Voors, Adriaan A., Damman, Kevin, Teerlink, John R., Angermann, Christiane E., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Ponikowski, Piotr
Publicado 2022

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

por Lewis, Gregory D., Gosch, Kensey, Cohen, Laura P., Nassif, Michael E., Windsor, Sheryl L., Borlaug, Barry A., Kitzman, Dalane W., Shah, Sanjiv J., Khumri, Taiyeb, Umpierrez, Guillermo, Lamba, Sumant, Sharma, Kavita, Khan, Sadiya S., Kosiborod, Mikhail N., Sauer, Andrew J.
Publicado 2023

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure

por Khariton, Yevgeniy, Nassif, Michael E., Thomas, Laine, Fonarow, Gregg C., Mi, Xiaojuan, DeVore, Adam D., Duffy, Carol, Sharma, Puza P., Albert, Nancy M., Patterson, J. Herbert, Butler, Javed, Hernandez, Adrian F., Williams, Fredonia B., McCague, Kevin, Spertus, John A.
Publicado 2018

Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction

por Thomas, Merrill, Khariton, Yevgeniy, Fonarow, Gregg C., Arnold, Suzanne V., Hill, Larry, Nassif, Michael E., Chan, Paul S., Butler, Javed, Thomas, Laine, DeVore, Adam D., Hernandez, Adrian F., Albert, Nancy M., Patterson, J. Herbert, Williams, Fredonia B., Spertus, John A.
Publicado 2021

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

por Kosiborod, Mikhail N., Angermann, Christiane E., Collins, Sean P., Teerlink, John R., Ponikowski, Piotr, Biegus, Jan, Comin-Colet, Josep, Ferreira, João Pedro, Mentz, Robert J., Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Voors, Adriaan A.
Publicado 2022

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Tri...

por Nassif, Michael E., Windsor, Sheryl L., Gosch, Kensey, Borlaug, Barry A., Husain, Mansoor, Inzucchi, Silvio E., Kitzman, Dalane W., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Shah, Sanjiv J., Umpierrez, Guillermo, Austin, Bethany A., Lamba, Sumant, Khumri, Taiyeb, Sharma, Kavita, Kosiborod, Mikhail N.
Publicado 2023

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

por Nassif, Michael E., Windsor, Sheryl L., Borlaug, Barry A., Kitzman, Dalane W., Shah, Sanjiv J., Tang, Fengming, Khariton, Yevgeniy, Malik, Ali O., Khumri, Taiyeb, Umpierrez, Guillermo, Lamba, Sumant, Sharma, Kavita, Khan, Sadiya S., Chandra, Lokesh, Gordon, Robert A., Ryan, John J., Chaudhry, Sunit-Preet, Joseph, Susan M., Chow, Chen H., Kanwar, Manreet K., Pursley, Michael, Siraj, Elias S., Lewis, Gregory D., Clemson, Barry S., Fong, Michael, Kosiborod, Mikhail N.
Publicado 2021

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

por Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Ponikowski, Piotr
Publicado 2022